Outcomes of adults with invasive meningococcal disease with reduced penicillin susceptibility in Auckland 2004–2017

Broom, Matthew; Best, Emma; Heffernan, Helen; Svensson, Susanne; Hygstedt, Maria Hansen; Webb, Rachel; Gow, Nick; Holland, David; Thomas, Mark G.; Briggs, Simon

doi:10.1007/s15010-022-01897-6

Cited by 7 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, we noted an increase over time in the proportion of isolates with reduced penicillin susceptibility. Similar trends have been reported among adults in Auckland, as well as in Spain and Australia (34)(35)(36). Earlier literature reported an association between reduced penicillin susceptibility and increased complications (37); however, no difference in outcomes were noted for our pediatric cohort or for the Auckland adult cohort (34).…”

Section: Discussionsupporting

confidence: 86%

“…Similar trends have been reported among adults in Auckland, as well as in Spain and Australia (34)(35)(36). Earlier literature reported an association between reduced penicillin susceptibility and increased complications (37); however, no difference in outcomes were noted for our pediatric cohort or for the Auckland adult cohort (34). New Zealand guidelines recommend a third-generation cephalosporin for empiric treatment of sepsis in children (38).…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020

Burton¹,

Best²,

Broom³

et al. 2023

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate. For CME questions, see page 874.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 86%

Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004–2020

Burton¹,

Best²,

Broom³

et al. 2023

Emerg. Infect. Dis.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sie beträgt 10-14 Tage für Streptococcus pneumoniae, 7-10 Tage für Haemophilus influenzae und 14-21 Tage für Listeria monocytogenes [8]. Meningokokkenerkrankungen sollen über 7-10 Tage behandelt werden, wahrscheinlich ist aber auch eine kürzere Therapie ausreichend [21]. Bei Vorliegen einer Infektion mit gramnegativen Enterobacteriaceae sollte die antibiotische Therapie über 21 Tage durchgeführt werden [8].…”

Section: Dauer Der Antibiotischen Behandlungunclassified

“…Standard der medizinischen Versorgung findet sich für Listerien mit 20-30%; Patienten mit Pneumokokkenmeningitis versterben in 6-15% der Fälle. Bei Patienten mit Meningokokkenmeningitis liegt die Sterblichkeit bei 3 bis 10% [1,17,21]. Bei Überlebenden sind neurologische Folgeschäden häufig (bei Pneumokokkenme-ningitis bei ca.…”

Section: Die Höchste Sterblichkeit In Ländern Mit Einem Hohenunclassified

“…Bei Überlebenden sind neurologische Folgeschäden häufig (bei Pneumokokkenme-ningitis bei ca. der Hälfte der überlebenden Patienten), dazu zählen Hörstörungen, neurokognitive Auffälligkeiten, Hemiparese, epileptische Anfälle und fokalneurologische Defizite [17,21]. Ein wichtiger Risikofaktor für einen ungünstigen Verlauf ist vor allem für Pneumokokken und Listerien ein höheres Lebensalter.…”

Section: Die Höchste Sterblichkeit In Ländern Mit Einem Hohenunclassified

See 1 more Smart Citation

Bakterielle Meningitis und Neurotuberkulose

Klein¹

2022

Neurologie up2date

View full text Add to dashboard Cite

Die akute bakterielle Meningitis ist eine schwere akute Erkrankung, ca. 15% der Patienten versterben 1 . Im Gegensatz zur akuten bakteriellen Meningitis handelt es sich bei der tuberkulösen Meningitis um eine subakut verlaufende Erkrankung. Die Neurotuberkulose ist in Deutschland selten, aufgrund der hohen Komplikationsrate und der schlechten Prognose ist es aber umso wichtiger, diese Diagnose frühzeitig in Betracht zu ziehen.

show abstract